Author(s): Xie X, Eberding A, Madera C, Fazli L, Jia W, et al.
Purpose: We explored the efficacy of the ginsenoside Rh2 and examined its impact on the effective dose of paclitaxel and mitoxantrone in the LNCaP prostate tumor model.
Materials and methods: Cultured LNCaP cell viability was assessed following treatment (48 hours) with Rh2 (0 to 40 microM) alone or in combination with paclitaxel and mitoxantrone. Synergism or antagonism observed when combining treatment was calculated using CalcuSyn software (Biosoft). In addition, the inhibition of LNCaP human xenograft tumor growth was examined in vivo when Rh2 treatment was combined with chemotherapy. Harvested tumors were immunohistochemical stained with p27kip and Ki67.
Results: Rh2 and paclitaxel act synergistically in cultured LNCaP cells to lower ED50 and ED75 values. Rh2 and mitoxantrone are also synergistic. However, when combined as ED95, an antagonistic effect was observed in this cell line. Treatment of LNCaP tumors by Rh2 plus paclitaxel produced a significant decrease in tumor growth and serum prostate specific antigen. Immunohistochemical analysis revealed an apparent but nonsignificant effect on proliferation markers in LNCaP tumors. When Rh2 and mitoxantrone were combined in vivo, there was no significant benefit observed.
Conclusions: These results indicate that the combination of Rh2 and paclitaxel has an effect on growth inhibition that is greater and synergistic, as demonstrated in a cultured LNCaP cell line. Conversely combining Rh2 with mitoxantrone appears to elicit no benefit. Therefore, combination therapy using chemotherapy and Rh2 requires further investigation.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/16600800
Author(s): Middleton E Jr, Kandaswami C, Theoharides TC
Author(s): Mozaffarian D, Rimm EB
Author(s): Calder PC, Yaqoob P
Author(s): Zuchi C, Ambrosio G, Luscher TF, Landmesser U
Author(s): Shukla SK, Gupta S, Ojha SK, Sharma SB
Author(s): Ceylan-Isik AF, Fliethman RM, Wold LE, Ren J
Author(s): Hsiao WL, Liu L
Author(s): Chan E, Tan M, Xin J, Sudarsanam S, Johnson DE
Author(s): Xiang YZ, Shang HC, Gao XM, Zhang BL
Author(s): Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP, et al.
Author(s): Weant KA, Smith KM
Author(s): Sander S, Coleman CI, Patel AA, Kluger J, White CM
Author(s): Shibata S, Fujita M, Itokawa H, Tanaka O, Ishii T
Author(s): Lu JM, Yao Q, Chen C
Author(s): Deng J, Lv XT, Wu Q, Huang XN
Author(s): Chan RY, Chen WF, Dong A, Guo D, Wong MS
Author(s): Hasegawa H, Uchiyama M
Author(s): Leung KW, Cheung LW, Pon YL, Wong RN, Mak NK, et al.
Author(s): Kitagawa I, Yoshikawa M, Yoshihara M, Hayashi T, Taniyama T
Author(s): Fei XF, Wang BX, Tashiro S, Li TJ, Ma JS, et al.
Author(s): Kim HS, Lee EH, Ko SR, Choi KJ, Park JH, et al.
Author(s): Hasegawa H, Sung JH, Matsumiya S, Uchiyama M, Inouye Y, et al.
Author(s): Jia WW, Bu X, Philips D, Yan H, Liu G, et al.
Author(s): Wang Z, Zheng Q, Liu K, Li G, Zheng R
Author(s): Zhang J, Zhou F, Wu X, Gu Y, Ai H, et al.
Author(s): Wang H, Zou H, Kong L, Zhang Y, Pang H, et al.
Author(s): Shangguan D, Han H, Zhao R, Zhao Y, Xiong S, et al.
Author(s): Kwon SW, Han SB, Park IH, Kim JM, Park MK, et al.
Author(s): Li L, Zhang JL, Sheng YX, Ye G, Guo HZ, et al.
Author(s): Yu K, Ma Y, Shao Q, Qu H, Cheng Y
Author(s): Li X, Sun J, Wang G, Hao H, Liang Y, et al.
Author(s): Joo KM, Lee JH, Jeon HY, Park CW, Hong DK, et al.
Author(s): Zhang X, Zhang D, Xu J, Gu J, Zhao Y
Author(s): Yang L, Xu SJ, Zeng X, Liu YM, Deng SG, et al.
Author(s): Qian T, Cai Z, Wong RN, Jiang ZH
Author(s): Xie HT, Wang GJ, Sun JG, Tucker I, Zhao XC, et al.
Author(s): Jiang L, Zhao S, Ya L, Li J
Author(s): Li XW, Gui MY, Zheng Y, Jin YR, Zhang HQ
Author(s): Xie HT, Wang GJ, Lv H, Sun RW, Jiang XL, et al.
Author(s): Gu Y, Wang GJ, Sun JG, Jia YW, Wang W, et al.